Opportunity Analyzer Allergic Rhinitis Allergen-Specific Immunotherapy and Forecast to 2018

Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales@researchmoz.us

Opportunity Analyzer Allergic Rhinitis Allergen-Specific Immunotherapy and Forecast to 2018

Summary

The global specific immunotherapy (SIT) market for allergic rhinitis (AR) is highly fragmented, with the US, Europe, and Japan having different SIT formulations available, under different regulatory restrictions, with almost no historical company crossover between markets. Europe has the most developed market, with subcutaneous immunotherapy (SCIT), sublingual immunotherapy (SLIT), and allergen immunotherapy tablets (AITs) all being available.

To Browse a Full Report with Toc: http://www.researchmoz.us/opportunityanalyzer-allergic-rhinitis-allergen-specific-immunotherapy-opportunity-analysis-and-forecast-to-2018-report.html

However, economy-driven healthcare expenditure restrictions have led to negative growth in European SIT sales for many companies, and in addition new German regulatory guidelines means now previously European-centric allergen extract manufacturers are partnering with US and Japanese pharmaceutical companies to distribute their therapies in the previously underdeveloped markets. In the US, the introduction of AITs will drive growth in the AR immunotherapies market, due to their high cost relative to standard subcutaneous allergen extracts. The total allergen extract immunotherapy market is expected to grow from $172.5m to $688.3m between 2013 and 2018. Japan, a market previously not widely treated with SIT, is set to see a new range of standardized, clinically-evaluated products containing the two most prevalent allergens, house dust mite (HDM) and Japanese cedar pollen. Available options will include AIT formulations previously unavailable in the market. GlobalData projects that the immunotherapy sales in Japan will reach $47.09m in 2018, with a CAGR of 70.24%.

Key Findings

- A...